Eversept Partners, LP

Q2 2018 13F Holdings Report, Restatement, Stock Holdings

Signature - Title
Ron Rosenstraus - Chief Financial Officer
Location
New York, NY
Holdings as of
30 Jun 2018
Value $
$204,139,040
Num holdings
67
Filing time
08 Nov 2023, 13:31:34 UTC
Form type
13F-HR/A-1 - Restatement
Description
All US holdings of this investor are reported in this report. Top holdings included QCP, RCM, AERI, RDUS, and GSK.
Previous filing
Q1 2018 - 08 Nov 2023
Next filing
Q3 2018 - 08 Nov 2023
SEC
View on sec.gov
Options Holdings
Showing stock holdings, see here for options holdings
Sym Weight Trade Impact Company Class Share Change Activity Value Change $ Value $ * Price $ Shares Principal
Filing 2018 Q2 - Restatement compared to 2018 Q1 - Restatement by default. Changes are calculated vs the previous SEC filing.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.

Person Signing this Report on Behalf of Reporting Manager:

Name Title City, State Date
Ron Rosenstraus Chief Financial Officer New York, United States 08 Nov 2023

Eversept Partners, LP ("Eversept") is filing this amendment primarily to correct our previous reporting of put and call option positions. In the Information Table in all reports on Form 13F filed from the fourth quarter of 2017 through the second quarter of 2023, Eversept had erroneously provided the requested information in columns 2-5 of the Information Table with respect to the put and call options themselves, rather than with respect to the securities underlying the options.